XML 314 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Cash Generated by Operations
12 Months Ended
Dec. 31, 2018
Text block [abstract]  
Cash Generated by Operations
28.    CASH GENERATED BY OPERATIONS         
   (Loss)/profit from continuing operations      (344.8      (20.8      167.9  
   Mining and income taxation      (65.9      173.2        189.5  
   Royalties      62.5        62.0        78.4  
   Interest expense      91.8        91.2        82.5  
   Interest received      (6.8      (5.1      (7.3
   Amortisation and depreciation      668.4        748.1        671.4  
   Interest expense – environmental rehabilitation      11.7        12.1        10.7  
   Non-cash rehabilitation income      (0.9      (13.5      (9.7
   Interest received – environmental trust funds      (0.6      (0.5   
   Impairment, net of reversal of impairment of investments and assets      520.3        200.2        76.5  
   Write-off of exploration and evaluation assets      37.7        51.5        41.4  
   Loss/(profit) on disposal of assets      51.6        (4.0      (48.0
   Profit on disposal of investments      —          —          (2.3
   Gain on acquisition of Asanko      (51.8      —          —    
   Unrealised loss/(gain) on derivative contracts2      36.6        (20.7      (14.4
   Fair value (gain)/loss on Maverix warrants2      (3.8      0.4        —    
   Profit on dilution of Gold Fields’ interest in Maverix      (4.0      —          —    
   Silicosis settlement costs2      (4.5      30.2     
   Share-based payments      37.5        26.8        14.0  
   Long-term incentive plan expense      1.1        5.0        10.5  
   Payment of long-term incentive plan      (17.8      (11.5      —    
   Borrowing costs capitalised      (17.5      (22.9      (15.1
   Share of results of equity accounted investees, net of taxation      0.2        (0.3      —    
   Other2      (3.0      (14.9      0.4  
     

 

 

    

 

 

    

 

 

 
   Total cash generated by operations      998.0        1,286.5        1,245.4  
     

 

 

    

 

 

    

 

 

 

2 

The item “Other” in 2017 and 2016 has been disaggregated into unrealised gain on derivative contracts, fair value loss on Maverix warrants and silicosis settlement costs.